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Abstract
Background: Current adaptive and dose escalating radiotherapy for muscle invasive bladder cancer requires
knowledge of both inter-fractional and intra-fractional motion of the bladder wall involved. The purpose of this
study is to characterize inter- and intra-fractional movement of the partial bladder wall using implanted fiducial
markers and a real-time tumor-tracking radiotherapy system.
Methods: Two hundred fifty one sessions with 29 patients were analysed. After maximal transurethral bladder
tumor resection and 40 Gy of whole bladder irradiation, up to six gold markers were implanted transurethrally into
the bladder wall around the tumor bed and used for positional registration. We compared the systematic and
random uncertainty of positions between cranial vs. caudal, left vs. right, and anterior vs. posterior tumor groups.
The variance in intrafractional movement and the percentage of sessions where 3 mm and 5 mm or more of
intrafractional wall movement occurring at 2, 4, 6, 8, 10, and at more than 10 min until the end of a session were
determined.
Results: The cranial and anterior tumor group showed larger interfractional uncertainties in the position than the
opposite side tumor group in the CC and AP directions respectively, but these differences did not reach significance.
Among the intrafractional uncertainty of position, the cranial and anterior tumor group showed significantly larger
systematic uncertainty of position than the groups on the opposite side in the CC direction. The variance of intrafractional
movement increased over time; the percentage of sessions where intrafractional wall movement was larger than 3 mm
within 2 min of the start of a radiation session or larger than 5 mm within 10 min was less than 5%, but this percentage
was increasing further during the session, especially in the cranial and anterior tumor group.
Conclusions: More attention for intrafractional uncertainty of position is required in the treatment of cranial and anterior
bladder tumors especially in the CC direction. The optimal internal margins in each direction should be chosen or a
precise intrafractional target localization system is required depending on the tumor location and treatment delivery time
in the setting of partial bladder radiotherapy.
Keywords: Bladder cancer, Interfractional uncertainty of position, Intrafractional uncertainty of position, Real-time tumor
tracking system
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Background
Many studies have reported comparable results for tri-
modality therapy, including transurethral resection of
bladder tumors, radiotherapy and chemotherapy of muscle
invasive bladder cancers, and standard surgical treatment
in selected patients [1–4]. Although a dose–response rela-
tionship in bladder cancer patients has been reported [5],
dose escalation for the whole bladder presents the risk of
global bladder dysfunction (contracted bladder). For this
reason, dose-escalated partial bladder radiotherapy has re-
cently been investigated to enable improvement of local
control [6–9].
The urinary bladder is a hollow organ which moves
mainly due to the urine inflow and it is commonly ac-
cepted that the position and volume of the bladder is con-
tinually changing. Large differences in urinary inflow rates
and initial bladder volumes between individuals have been
reported even when patients have received drinking and
voiding instructions [10–12]. Therefore, when administer-
ing radiotherapy for bladder cancer, adding at least 2 cm
margins has been considered to be required to compen-
sate for the uncertainties in size [13–17]. However, this
large margin and treatment field may later result in tox-
icity, especially for the bowels [18–20].
Recently, a number of image guidance technologies such
as cone-beam computed tomography (CBCT), ultrasonog-
raphy, cine-magnetic resonance imaging (MRI), and in-
ternal fiducial markers (spherical gold seeds, titanium clips,
or lipiodol) have been rigorously assessed [11, 12, 21–24].
In addition, image-guided adaptive radiotherapy is reported
to be useful to reduce the CTV to PTV (clinical target vol-
ume to planning target volume) margin without reducing
the CTV coverage, with a consequent reduction in the dose
to surrounding normal tissue and to the volume of the
small bowel [25–28]. Although these image guidance and
adaptive protocols based on the imaging just before the ini-
tiation of radiotherapy are effective to reduce CTV to PTV
margins for interfractional bladder wall movements, it is
also necessary to pay attention to intrafractional wall move-
ment to prevent subsequent insufficient dose delivery due
to the smaller CTV to PTV margins. Based on the pre- and
post-treatment CBCT or repeat MRI series, 5–12 mm an-
isotropic margins have been suggested to cover intrafrac-
tional positional uncertainties and the largest movement
has been reported to be in the cranial anterior direction
[29–31]. The movement of the whole bladder was analysed
in these studies, however, the inter- and intra-fractional un-
certainty of position of the partial bladder wall are still not
clearly established.
Real-time tumor-tracking radiotherapy (RTRT) sys-
tems have the advantage that they enable corrections of
the target location and also make it possible to observe
the location of the target using the fiducial markers dur-
ing the beam delivery [32]. We have previously reported
about intrafractional prostate motion in prostate cancer
radiotherapy [33], and have applied the same technique
to treat locally advanced bladder cancers with encour-
aging results [34].
The aim of the study here is to evaluate inter- and
intra-fractional positional uncertainty of the partial blad-
der wall during radiotherapy.
Methods
Patients
Thirty-three patients were treated for bladder tumors
and administered radiotherapy with a localized boost
from 1999 to 2016 with the RTRT system using fiducial
markers for the positioning (details specified below). Of
these, one patient was excluded because the tumor had
massively invaded into the prostate and its motion was
expected to be different from that of normal bladders. In
addition, 3 other patients who were treated in 1999 were
excluded from the analysis because position tracking
data had been lost. Finally, 29 patients were included in
this retrospective study. Patient particulars, tumor
stages, and details of the tumor locations on the bladder
wall are shown in Tables 1 and 2. Except for one T3 pa-
tient, all of T3 and T4 tumors located in the caudal half
of the bladder. By using the RTRT system and the im-
planted fiducial markers, we are able to see the move-
ments of the part of the bladder wall where the tumor is
located; however, we cannot assess the movements of
other parts of the bladder wall. As a result we assessed
the movement of only one wall segment, that where the
tumor was located, for one patient. The patients were di-
vided into eight subgroups based on the primary loca-
tion of the tumor, according to the 2x2x2 combinations
of cranial or caudal, left or right, and anterior or poster-
ior. To compare between cranial vs. caudal bladder wall
movement, we defined the cranial tumor group as the
four cranial subgroups and the caudal tumor group as
the four caudal subgroups. In the same way, we com-
pared between left vs. right and anterior vs. posterior
tumor group to assess left vs. right and anterior vs. pos-
terior bladder wall movement.
Treatment
Maximal transurethral resection of the bladder tumors
(TUR-BT) was followed by 40 Gy irradiation in 16–20
Table 1 Patient characteristics
Median age – years (range) 78 (58–90)
Gender – No. Male 20
Female 9
Tumor stage – No. (%) T2 21 (72%)
T3 6 (21%)
T4 2 (7%)
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fractions to the whole bladder with an isotropic margin
of 15–20 mm. Implantation of fiducial markers was per-
formed after the delivery of the 40 Gy to minimize the
duration between the implantation and the end of the
radiotherapy and to avoid loss of markers. One or two
markers were transurethrally implanted in the bladder
wall of each patient around the primary tumor bed (the
TUR-BT scar) before January 2002. Later, from February
2002, the practice was changed, and four to six markers
were implanted around the primary tumor bed. Of the
29 patients, 6 patients had been treated before January
2002 and 23 patients after. The interruption of RT to
implant the markers was scheduled to be less than
12 days. A localized boost of the primary tumor bed
(25 Gy/10 fractions) was given using the RTRT for target
positioning. All patients were treated using three-
dimensional conformal radiotherapy. We have reported
details of the methods and results elsewhere [34].
Patient data acquisition and treatment planning for the
local boost
Computed tomography (CT) images, in 1.25–2 mm slices,
of the small pelvis were used for the treatment planning.
Until 2004, the CT scanning was preceded by intravesical
instillation of 100 ml sterile normal saline to ensure a con-
stant bladder volume. The pre-scanning procedure was
changed in 2005: now patients were instructed to avoid
urination for 30 min before the CT scanning to allow the
bladder to fill with urine. All treatments were adminis-
tered 30–60 min after the last voiding.
The coordinates of the fiducial markers and the target
volumes were determined on a three-dimensional radiation
treatment planning (3D-RTP) system using the CT images.
Positioning procedure using the RTRT system
The RTRT system consists of a linear accelerator, two
diagnostic X-ray fluoroscopes in the linear accelerator
room, image processing units and an image display unit
(originally Mitsubishi; before replacement with one
from Varian Medical Japan Co., Tokyo), as reported
elsewhere [21]. The actual position of the markers can
be visualized on the fluoroscopic image screen during
the irradiation. The planned marker position is trans-
ferred from the 3D-RTP and superimposed on the dis-
play unit screen of the RTRT system. The required
distance to correct the position was derived using the
RTRT system. After completing the manual setup using
skin markings in the supine position, the patient couch
was moved so that the markers moved to the planned
position (fiducial marker registration) (Fig. 1c and d
show an example). For the positional registration, the
center of gravity of three markers or the position of one
of the markers was used. The center of gravity of three
Table 2 Tumor locations, stages and subgroups
Cranial Caudal

















The capital letters (A-H) indicate the name of subgroups and with patient
numbers. The breakdown of patients by tumor stage is also shown. The cranial
and caudal tumor groups consist of subgroups A, B, C, and D (n = 13) and E, F,
G, and H (n = 16), respectively. In the same way, the anterior and posterior
tumor groups consist of subgroups A, B, E, and F (n = 11) and C, D, G, and H
(n = 18), respectively. The left and right tumor groups consist of subgroups A,
C, E, and G (n = 14) and B, D, F, and H (n = 15), respectively
Fig. 1 Example of fiducial marker registration. a X-ray of patient
abdomen with the tumor located in the right bladder wall. This patient
had 6 gold markers implanted around the transurethral resection of the
bladder tumor (TUR-BT) scar. b Arrangement of the fluoroscopic units
with the direction of the X-ray beam (arrows). The images were acquired
by the two units that are a part of the RTRT system. c The colored circles
in the fluoroscopic image indicate the gold marker positions at the
registration and the black dots represent the actual positions of the gold
markers. Up to three markers could be displayed in this system. The red
arrow indicates the direction of the required positional correction. d
Fluoroscopic images after fiducial marker registration. The red circles
indicate the fiducial markers placed at the planned position
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selected markers was used for patients who had more
than three markers implanted. For patients who had
fewer than three markers implanted, one of the markers
identified as that nearest to the isocenter was used. If
the positional relationship of the markers was consid-
ered to be changed from that on the treatment plan-
ning CT, an additional CT scan was performed to
identify each marker and confirm the cause of the posi-
tonal change. During the treatment, the position of the
fiducial markers was continuously observed. If neces-
sary, the treatment was interrupted and the operator
could correct the patient position; the threshold used in
this study was a 2.0 mm discrepancy from the planned
position of the center of gravity of three markers or the
position of a single marker in each of the cranial-caudal
(CC), left-right (LR) and anterior-posterior (AP) direc-
tions. A positive(+) shift represents a translation in the
cranial (Cranial +), left (Left+) and anterior (Anterior+)
directions.
Of the 29 patients, 28 were treated with 10 irradiation
sessions as planned using the RTRT system; one patient
wanted, for religious reasons, to avoid the risk of need-
ing a blood transfusion in case of side-effects and the
boost radiotherapy for this patient was terminated at
20 Gy/8 fractions; as a result datasets for a total of 288
sessions were obtained. Of these datasets, 37 sessions
were excluded because of insufficient records or breaks
in the treatment caused by the general condition of the
patients involved. Finally, datasets for 251 (87%) sessions
were used for the analysis.
Fig. 2 The magnitudes of wall movements in the primary six directions plotted vs time before and after the initial setup at the start of each session.
The horizontal axis shows the time in minutes from the initial setup. The vertical axis represents the magnitude of the wall movements in millimeters.
The magnitude in the CC, LR, and AP directions in the different graphs are plotted at the same scales. The dotted transverse lines indicate the range of
+/− 3 mm wall movements and the broken lines indicate the range of +/− 5 mm wall movements
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Analysis of wall movements during and between fractions
The marker position at the start of the radiation dose
delivery was assigned as the reference position; the pre-
treatment shifts between skin marker registration and fi-
ducial marker registration were considered as wall
movements between fractions (interfractional wall move-
ments), and the shifts of the fiducial markers from the
reference position after the start of the treatment were
assigned as wall movements during a fraction (intrafrac-
tional wall movements).
The total systematic uncertainty of position (Σ) and
the overall random uncertainty of position (σ) for both
of inter- and intra-fractional bladder wall movements
were calculated, and the average of the systematic blad-
der wall movements of the whole population is the mean
overall uncertainty of position (M). The Σ is calculated
as the standard deviation of all of the individual system-
atic uncertainties of position, and the σ is the quadratic
average of all the random uncertainties of position. To
calculate the intrafractional Σ and σ, we used the max-
imum wall movement from the reference position at the
end of session along each direction not to underestimate
intrafractional movement. For instance, if wall move-
ments of 3 mm and 2 mm in the same direction were
observed sequentially, the final wall movement would be
assigned as 5 mm. On the other hand, if there was a
subsequent wall movement of 2 mm in opposite direc-
tion to the initial 3 mm movement, the wall movement
remained 3 mm even though the final position was lo-
cated only 1 mm away from the reference position.
In addition to Σ and σ, the variance of the intrafractional
movement and the percentage of the sessions with 3 mm
and 5 mm or larger intrafractional wall movements oc-
curred at 2, 4, 6, 8, 10, and longer than 10 min until the
end of a session were determined to characterise the
details of intrafractional motion. The variance of each
tumor group was calculated as the mean of all of the indi-
vidual variances.
We compared the uncertainties of position between cra-
nial vs. caudal, left vs. right, and anterior vs. posterior
tumor group in the CC, LR and AP directions, respectively.
The mean overall uncertainty of position was compared
using an unpaired Welch’s t-test, the systematic uncertainty
of position using Levene’s test for equality of variance and
the random uncertainty of position using the Mann-
Whitney test. Because three separate hypotheses (cranial vs.
caudal, left vs. right and anterior vs. posterior) were tested,
the significance level was set at 0.05 / 3 after the Bonferroni
correction. All statistical analyses were performed using
JMP Pro 12.0.1 (SAS Institute, Cary, NC, USA).
Results
The ranges of the interfractional wall movements (5% and
95% quantiles) were −31.3 to 22.5 (−13.6 and 10.8), −21.7
to 15.8 (−7.3 and 7.1), and −26.1 to 18.7 (−10.0 and 7.7)
mm along the CC (Cranial +), LR (Left +), and AP (Anter-
ior +) directions, respectively. The ranges of the intrafrac-
tional wall movements (5% and 95% quantiles) were −5.3
to 14.7 (−2.1 and 4.4), −13.3 to 4.4 (−2.0 and 2.1), and
−9.5 to 8.9 (−3.0 and 2.8) mm along the CC, LR, and AP
directions. The incidence of sessions requiring realign-
ment due to intrafractional wall movements was 35.9%.
The number of realignments in a session after the initial
patient setup for all treatments was from 0 to 4, and more
than two adjustments were required in 35 sessions with
14 patients. Figure 2 shows the magnitudes of the wall
movements in the primary six directions plotted against
time before (interfractional) and after (intrafractional) the
initial setup at the start of all sessions.
Table 3 Interfractional uncertainty of position (mm) and p-
values of the comparison tests
Tumor location
group
CC direction LR direction AP direction
M Σ σ M Σ σ M Σ σ
CC
group
Cranial −1.2 4.5 5.0 0.1 3.1 3.1 −1.0 3.5 4.7
Caudal −1.0 2.6 6.9 0.9 2.0 4.1 0.0 3.0 4.8
p-value 0.92 0.09 0.57 0.41 0.20 0.25 0.43 0.44 0.18
LR
group
Left −1.8 4.6 5.1 0.4 3.1 4.0 0.7 3.0 5.0
Right −0.5 2.0 7.0 0.7 1.9 3.4 −1.6 3.0 4.5
p-value 0.36 0.02 0.91 0.78 0.27 0.68 0.05 0.89 0.95
AP
group
Anterior −2.3 3.4 7.4 1.4 2.3 3.4 −1.2 4.3 4.5
Posterior −0.4 3.7 5.2 0.0 2.6 3.9 0.0 2.3 4.9
p-value 0.15 0.80 0.80 0.15 0.95 0.95 0.44 0.04 0.91
Overall −1.1 3.5 6.1 0.5 2.5 3.7 −0.5 3.2 4.8
Abbreviations: M mean overall uncertainty of position, Σ systematic uncertainty
of position, σ random uncertainty of position, CC cranial-caudal, LR left-right,
AP anterior-posterior
Table 4 Intrafractional uncertainty of position (mm) and p-
values of the comparison tests
Tumor location
group
CC direction LR direction AP direction
M Σ σ M Σ σ M Σ σ
CC
group
Cranial 0.8 2.2 1.9 0.0 0.6 1.1 -0.4 0.7 2.0
Caudal 0.0 0.3 1.4 -0.1 0.5 1.6 0.1 0.5 1.4
p-value 0.20 0.01 0.44 0.48 0.91 0.47 0.06 0.53 0.24
LR
group
Left 0.0 0.4 1.6 0.0 0.2 1.3 -0.1 0.5 1.1
Right 0.7 2.0 1.7 -0.2 0.7 1.5 -0.2 0.7 2.1
p-value 0.22 0.03 0.95 0.32 0.01 0.33 0.57 0.82 0.25
AP
group
Anterior 1.0 1.0 1.9 0.0 0.6 1.3 -0.2 0.2 1.9
Posterior 0.0 0.4 1.5 -0.1 0.5 1.5 -0.1 0.8 1.5
p-value 0.19 <0.01 0.79 0.76 0.76 0.54 0.76 0.09 0.98
Overall 0.4 1.5 1.6 -0.1 0.5 1.4 -0.1 0.6 1.7
Abbreviations M mean overall uncertainty of position, Σ systematic uncertainty
of position, σ random uncertainty of position, CC cranial-caudal, LR left-right,
AP anterior-posterior
Bold: significant difference between two groups (p < 0.05 / 3)
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The overall mean uncertainty of position (M), the total
systematic uncertainty of position (Σ), and the overall
random uncertainty of position (σ) for both inter- and
intra-fractional bladder wall movements are shown in
Tables 3 and 4.
Overall, the interfractional movement of tumors in the
cranial tumor groups showed larger Σ than in the caudal
tumor groups in the CC direction, and the anterior
tumor groups showed larger Σ than the posterior tumor
groups in the AP direction. The left-sided tumor groups
also showed larger Σ than the right-sided tumor groups
in the CC direction, but these differences did not reach
significance.
The intrafractional motion showed significantly larger
Σ in the CC direction with the cranial and anterior
tumor groups. In addition, the right-sided tumor groups
showed larger Σ in the LR directions than the left-sided
tumor groups.
The variances per time segment are shown in Fig. 3.
In general, the variance increased over time, however,
the incremental variances of the cranial tumor and an-
terior tumor group in the CC and AP directions were
prominent. The percentage of the sessions where intra-
fractional wall movements were determined for the cra-
nial vs caudal, left vs right, and anterior vs posterior
tumor groups are shown in Fig. 4. In the CC direction,
the percentage of the sessions where 3 mm or larger wall
movements occurred was increasing over time in a treat-
ment session in patients with cranial, anterior, and right
tumors, while there was little or no change with caudal
and posterior tumors. Sessions with 5 mm or larger wall
movements occurred within 10 min in fewer than 5% of
the sessions, but there were steadily increasing wall
movements especially in the cranial, anterior, and right
tumor groups. The percentages of sessions with 3 mm
and 5 mm or larger wall movement in the AP direction
was larger than in the LR direction. There were no clear
relationships between the tumor location and the per-
centage of sessions with 3 mm and 5 mm or larger wall
movement in the AP and LR direction.
Discussion
With advances in image guidance technology, CBCT is
now commonly used to assess interfractional and intra-
fractional bladder wall movements. For interfractional
bladder movements, a study by Yee et al. reported on
daily CBCT for bladder cancer radiotherapy that there
were significant large individualized interfractional varia-
tions in bladder size and position during a course of
radiotherapy [24]. Foroudi et al. reported intrafractional
bladder motion estimated from pretreatment and post-
treatment CBCT images where the margins are required
to cover the intrafractional bladder changes, in mm from
pretreatment to posttreatment, were 12.5 (range, 11.9–
Fig. 3 The variances in the intrafractional movement per time segment. The horizontal axis shows the time at 2, 4, 6, 8 and 10 min after the
initial setup and the final point is the end of session. The vertical axis represents the variance of the intrafractional bladder wall movement. The
variances in the cranial vs. caudal, left vs. right, and anterior vs. posterior tumor groups in the CC, LR, and AP directions are shown together
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15.0) in the superior, 6.7 (range, 5.8–11.2) in the inferior,
7.4 (range, 5.9–9.4) in the right, 7.3 (range, 5.1–10.0) in
the left, 12.0 (range, 8.5–13.2) in the anterior, and 8.6
(range, 7.3–9.9) in the posterior directions [29]. Foroudi
et al. assessed changes of position and volume of the
whole bladder between the start and the end of the
treatment; however, they could not observe the motion
of the tumor-involved bladder wall during the actual
treatment. The advantage of the RTRT system is its abil-
ity to assess positional changes of the involved bladder
wall part continuously during the actual beam delivery.
Our data showed large interfractional bladder wall
movements especially in the CC direction and smaller
movements in the LR direction. The interfractional un-
certainty of position is generally larger than intrafrac-
tional uncertainty of positions. It indicates that the large
CTV to PTV margins for interfractional bladder move-
ment over-compensate intrafractional movement after
the image guided registration. In the intrafractional blad-
der wall movements, the percentage of sessions where
3 mm or more of wall movements were determined was
increasing during the time of the treatment but that of
5 mm or larger wall movements was less than 5% within
10 min. These results are consistent with previous re-
ports. The patients with tumors in the right bladder wall
in our series showed a higher incidence of intrafractional
wall movements larger than 3 mm in the CC direction
than tumors in the left bladder wall. The reasons for this
difference are not clear. One possible reason could be
that the small bowel or cecum deformed the bladder
wall, but further investigation is needed to obtain more
details of patient-specific and region-specific bladder
wall movements during radiotherapy.
There are several limitations to the study. First, the fi-
ducial markers implanted around the tumor bed were
surrogates of the bladder wall and may be different from
the motion of the bladder wall itself. Based on our pub-
lished clinical results using the same registration tech-
nique, we believe that the markers represented bladder
wall positions well [34]. Second, the number of markers
implanted and the registration method was changed in
February 2002. If the positional relationship of the
markers was remarkably changed from that at the treat-
ment planning CT, the positional relationship between
the isocenter and the center of gravity of the three
markers or single marker could change. We acquired
Fig. 4 The percentage of the sessions where 3 mm and 5 mm or more of intrafractional wall movements occurred. a, b, and c show the percentage
of the sessions that 3 mm or more of intrafractional wall movements within 2(dark blue), 4(blue), 6(green), 8(yellow), 10(orange) minutes, and after more
than 10 min (red) for each tumor location group in the Cranial-Caudal, Left-Right, and Anterior-Posterior directions, respectively. Similarly, (D), (E), and
(F) show the percentages of sessions with 5 mm or more of intrafractional wall movements in each direction
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additional CT scans and confirmed the positional rela-
tionship if positional changes in the markers were sus-
pected, however, we believe any consequences of the
differences arising from the number of markers was
small. Third, this study is retrospective and the patient
number is too small to analyze the partial bladder wall
movements and the deformation of the bladder in detail.
It would be valuable to be able to analyze the possible
effect of the bladder volume on the interfractional and
intrafractional bladder wall movements and its interplay
with the marker positions and also on the anatomical re-
lationships between the markers and other organs, such
as bowels and bones during the irradiation.
Conclusions
Large CTV to PTV margins for interfractional bladder
movement might over-compensate intrafractional move-
ment in the image guided radiotherapy era. The cranial and
anterior tumors showed larger intrafractional uncertainties
of position than the caudal and posterior tumor group es-
pecially in the CC direction. A 5 mm internal margin would
be sufficient if the treatment finishes within 10 min after
the initial image-guided registration, but special attention is
recommended for cranial and anterior tumors. Optimal in-
ternal margins in each direction should be chosen or a pre-
cise intrafractional target localization system is required
depending on the tumor location and treatment delivery
time in the setting of the partial bladder radiotherapy.
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